

# CCL17 Antibody

Purified Rabbit Polyclonal Antibody (Pab)

Catalog # AP21571a

## Product Information

---

Application	WB, FC, E
Primary Accession	<a href="#">Q92583</a>
Reactivity	Human
Host	Rabbit
Clonality	polyclonal
Isotype	Rabbit IgG
Clone Names	RB53078
Calculated MW	10507

## Additional Information

---

Gene ID	6361
Other Names	C-C motif chemokine 17, CC chemokine TARC, Small-inducible cytokine A17, Thymus and activation-regulated chemokine, CCL17, SCYA17, TARC
Target/Specificity	This CCL17 antibody is generated from a rabbit immunized with a recombinant protein of human CCL17.
Dilution	WB~~1:2000 FC~~1:25 E~~Use at an assay dependent concentration.
Format	Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	CCL17 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

## Protein Information

---

Name	CCL17
Synonyms	SCYA17, TARC
Function	Chemokine, which displays chemotactic activity for T lymphocytes, preferentially Th2 cells, but not monocytes or granulocytes. Therefore plays an important role in a wide range of inflammatory and immunological processes (PubMed: <a href="#">8702936</a> , PubMed: <a href="#">9169480</a> ). Acts by binding to CCR4 at

T-cell surface (PubMed:[10540332](#), PubMed:[9169480](#)). Mediates GM-CSF/CSF2-driven pain and inflammation (PubMed:[27525438](#)). In the brain, required to maintain the typical, highly branched morphology of hippocampal microglia under homeostatic conditions. May be important for the appropriate adaptation of microglial morphology and synaptic plasticity to acute lipopolysaccharide (LPS)-induced neuroinflammation (By similarity). Plays a role in wound healing, mainly by inducing fibroblast migration into the wound (By similarity).

#### Cellular Location

Secreted

#### Tissue Location

Constitutively expressed in thymus. Detected at lower levels in the lung, colon and small intestine (PubMed:[8702936](#)) Expressed in stimulated peripheral blood mononuclear cells, but not in resting cells (PubMed:[8702936](#)).


## Background

Chemotactic factor for T-lymphocytes but not monocytes or granulocytes. May play a role in T-cell development in thymus and in trafficking and activation of mature T-cells. Binds to CCR4.


## References

- Imai T.,et al.J. Biol. Chem. 271:21514-21521(1996).  
 Livingston R.J.,et al.Submitted (OCT-2006) to the EMBL/GenBank/DDBJ databases.  
 Loftus B.J.,et al.Genomics 60:295-308(1999).  
 Mural R.J.,et al.Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.  
 Bernardini G.,et al.Eur. J. Immunol. 28:582-588(1998).

## Images



Overlay histogram showing Jurkat cells stained with AP21571a (green line). The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min. The cells were then incubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (AP21571a, 1:25 dilution) for 60 min at 37°C. The secondary antibody used was Goat-Anti-Rabbit IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed(OH191631) at 1/200 dilution for 40 min at 37°C. Isotype control antibody (blue line) was rabbit IgG (1µg/1x10<sup>6</sup> cells) used under the same conditions. Acquisition of >10, 000 events was performed.



All lanes : Anti-CCL17 Antibody at 1:2000 dilution Lane 1: human spleen lysates Lane 2: human skeletal muscle lysates Lane 3: human lung lysates Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 11 kDa Blocking/Dilution buffer: 5% NFDM/TBST.

## Citations

---

- [Transcriptome analysis reveals GPNMB as a potential therapeutic target for gastric cancer.](#)

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.